AtriCure(ATRC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In 2025, total revenue reached $534 million, reflecting a 15% growth over 2024, with adjusted EBITDA of nearly $62 million and cash generated of $45 million [5][29] - For Q4 2025, worldwide revenue was $140.5 million, representing a 13.1% increase compared to Q4 2024, with U.S. revenue growing 12.6% to $114.3 million [20][24] - Full-year 2025 adjusted EBITDA was $61.8 million, compared to $31.1 million in 2024, with a loss per share of $0.24, improved from a loss of $0.95 in 2024 [29] Business Line Data and Key Metrics Changes - Pain management revenue grew 33% in 2025, with Q4 growth of 24%, driven by the adoption of the cryoSPHERE MAX device [12][13] - Appendage management saw a 19% increase in worldwide revenue for 2025, with Q4 growth of 15%, primarily due to the AtriClip FLEX-Mini and PRO-Mini devices [14][15] - Open ablation revenue increased by 16.3% in 2025, with the EnCompass Clamp contributing over 60% of U.S. open ablation revenue [25][26] Market Data and Key Metrics Changes - International revenue totaled $99.2 million in 2025, up 20.2% on a reported basis, despite a decline in the U.K. due to funding and reimbursement uncertainties [25][22] - The U.K. market, previously the fastest-growing in Europe, saw a significant drop in revenue, impacting overall international sales [22][80] Company Strategy and Development Direction - The company aims for sustained double-digit revenue growth, with a 12%-14% growth forecast for 2026, focusing on innovation and market expansion [6][30] - Strategic initiatives include the LeAAPS and BoxX-NoAF clinical trials, which are expected to unlock significant market opportunities [8][12] - The company is committed to expanding its presence in surgical pain management and cardiac surgery, with a focus on innovative product launches [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the competitive landscape, viewing new entrants as validation of market potential, and noted that competition has historically driven revenue growth [39][40] - The company remains cautiously optimistic about the minimally invasive ablation market, anticipating a moderated decline in revenue in 2026 [30][32] - Management highlighted the importance of ongoing clinical trials and product innovation to maintain leadership in the market [42][76] Other Important Information - The company ended 2025 with $167.4 million in cash and investments, reflecting efficient capital management [29] - Gross margin for 2025 was 75%, an increase driven by favorable product mix and production efficiencies [27][22] Q&A Session Summary Question: Impact of competitor entering the market - Management acknowledged the competitive entry as a validation of the market, noting that it has historically led to increased revenue growth [39][40] Question: Update on LeAAPS trial data - Management confirmed that the trial is ongoing and received positive feedback from the Data Safety Monitoring Board, but specific data release timelines were not provided [42][43] Question: Guidance for 2026 amid new competition - Management stated that the guidance for 2026 already factored in mild competitive pressures and remains confident in achieving 12%-14% growth [47][48] Question: Softness in U.S. appendage management - Management noted a decline in minimally invasive clips but highlighted strong growth in open appendage management, driven by the FLEX-Mini clip [49][50] Question: Revenue contribution from LeAAPS trial - Management confirmed that they receive payment for devices used in the trial, but the overall impact on revenue during enrollment was minimal [53][54] Question: Future enhancements for EnCompass - Management indicated no new product iterations are planned for EnCompass but emphasized ongoing marketing efforts and trial participation to drive adoption [57][58] Question: International sales impact from U.K. budget issues - Management reported significant impacts on pain management and minimally invasive ablation segments in the U.K. due to reimbursement changes [80][81]